Spyre Therapeutics Has Initiated Dosing Of Healthy Volunteers In Its First Clinical Trial Of SPY001 For Inflammatory Bowel Disease, Interim Subcutaneous Pharmacokinetic And Safety Data Anticipated By End Of 2024
$SYRE
Biotechnology: Pharmaceutical Preparations
Health Care
- Preclinical data for SPY001 demonstrate the potential for improved dosing over standard of care, including the potential for dosing every eight or twelve weeks compared to dosing every two weeks for subcutaneous vedolizumab.
- SPY002, an extended half-life anti-TL1A antibody designed for enhanced potency to both TL1A monomers and trimers, remains on track to begin first-in-human studies in the second half of 2024.
- All three next-generation antibodies targeting α4β7, TL1A, and IL-23 are on track to be in the clinic within 12 months, each serving as backbones for potential best-in-class combinations